13 completed. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
Follow Leishmaniasis, Visceral: new trials by email Literature Review of Leishmaniasis, Visceral trials Research Report on Leishmaniasis, Visceral
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Miltefosine, Paromomycin, Sodium stibogluconate - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 439 | 2018-01-24 | 2024-02-29 |
| Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Liposomal Amphotericin B, Miltefosine - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 59 | 2014-07-01 | 2019-04-08 |
| Miltefosine for Children With PKDL Miltefosine - Post Kala Azar Dermal Leishmaniasis | Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 80 | 2014-07-01 | 2019-08-21 |
| Replacement of Insecticides to Control Visceral Leishmaniasis (VL) IWFPL, IDWL, ITN - Cost-effective and Sustainable Vector Control Methods Will be Established to Reduce VL in India, Bangladesh and Nepal | Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 3600 | 2012-05-01 | 2017-08-29 |
| Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Pentamidine - Visceral Leishmaniosis, HIV-infection/Aids | Phase 3 | Completed | Institute of Tropical Medicine, Belgium | 74 | 2011-11-01 | 2019-02-15 |
| Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Liposomal amphotericin B, liposomal amphotericin B + miltefosine, liposomal amphotericin B + paromomycin - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 602 | 2010-05-01 | 2016-01-21 |
| To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Amphotericin B Lipid emulsion, Liposomal Amphotericin B - Leishmaniasis, Visceral | Phase 3 | Completed | Bharat Serums and Vaccines Limited | 500 | 2009-07-01 | 2011-06-02 |
| Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Amphotericin B Deoxycholate, Ambisome + Miltefosine, Ambisome and Paromomycin - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 634 | 2008-06-01 | 2010-02-11 |
| An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Paromomycin - Visceral Leishmaniasis | Phase 3 | Completed | Banaras Hindu University | 329 | 2008-02-01 | 2008-09-12 |
| Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Liposomal Amphotericin B, amphotericin B deoxycholate - Visceral Leishmaniasis | Phase 3 | Completed | Banaras Hindu University | 400 | 2008-02-01 | 2009-04-03 |
| Combination Therapy in Indian Visceral Leishmaniasis amphotericin B deoxycholate, Liposomal Amphotericin B with Miltefosine, Liposomal Amphotericin B and Paromomycin Sulfate - Leishmaniasis, Visceral | Phase 3 | Completed | Banaras Hindu University | 624 | 2007-09-01 | 2010-05-26 |
| Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Sodium Stibogluconate, Paromomycin sulphate, SSG and Paromomycin sulphate - Visceral Leishmaniasis | Phase 3 | Completed | Drugs for Neglected Diseases | 1142 | 2004-11-01 | 2016-03-22 |
| Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Paromomycin sulfate, Amphotericin B - Visceral Leishmaniasis | Phase 3 | Completed | PATH | 667 | 2003-06-01 | 2014-10-03 |
Acquired Immunodeficiency Syndrome (1) · Recurrence (1)
Euglenozoa Infections (13) · Infections (13) · Leishmaniasis (13) · Parasitic Diseases (13) · Protozoan Infections (13) · Vector Borne Diseases (13) · Blood-Borne Infections (1) · Communicable Diseases (1) · Disease Attributes (1) · Genital Diseases (1) · HIV Infections (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Lentivirus Infections (1) · Pathologic Processes (1)
Paromomycin (7) · liposomal amphotericin B (6) · miltefosine (6) · amphotericin B, deoxycholate drug combination (3) · Antimony Sodium Gluconate (2) · Amphotericin B (1) · Insecticides (1) · Pentamidine (1)
Drugs for Neglected Diseases (5) · Banaras Hindu University (3) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · Bharat Serums and Vaccines Limited (1) · Institute of Tropical Medicine, Belgium (1) · PATH (1)
India (6) · Ethiopia (4) · Bangladesh (3) · Kenya (2) · Sudan (2) · Uganda (2)
Shyam Sundar, MD (3) · Ahmed M Musa, MD, Prof (1) · Dr. Gautam Daftary, MBBS (1) · Dr. S.K. Bhattacharya (1) · Ermias Diro, Dr. MD (1) · Ermias Diro, MD (1) · Farrokh Modabber (1) · Jane Mbui, MD (1) · Johan Van Griensven, MD, PhD (1) · Joseph Olobo, MD, Prof (1) · Manica Balasegaram (1) · P K Sinha, MD (1) · Prof C.P. Thakur (1) · Prof S. Sundar (1) · Prof T.K. Jha (1)
PMID 17582067, PMID 19663597, PMID 20147716, PMID 21049063, PMID 21255828, PMID 22724029, PMID 25233346, PMID 27188804, PMID 28558062, PMID 29020217, PMID 30653490, PMID 30789910, PMID 36164254